The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Serum Prostate Specific Antigen as Pre-Screening Test for Prostate Cancer
Abstract
Prostate cancer has become the most common cancer and the second cause of death due to cancer in men in North America. Since curative therapies are limited to early stages of the disease, the availability of an efficient, easy to perform, widely acceptable and cost-effective method of early detection of prostate cancer is particularly important. Thus, digital rectal examination, transrectal ultrasonography of the prostate as well as measurements of serum prostate specific antigen (PSA) were performed independently in a series of 1,002 men between 45 and 80 years old randomly selected from the electoral rolls of Quebec City and its vicinity as part of a screening program for prostate cancer. Using this population of randomly chosen men, various cutoff serum PSA values were selected in an attempt to find the optimal decision threshold that would indicate a much greater risk of having prostatic cancer. At a threshold value of 3.0 micrograms./l. the sensitivity and specificity of the test are 80.7 and 89.6%, respectively, while the area under the receiver operating characteristic curve reflecting the accuracy of the test is 87.8 +/- 3.3% (plus or minus standard deviation). Moreover, the negative predictive value was estimated at 98.6%, thus leaving only a 1.4% chance of missing cancer when the serum PSA value was 3.0 micrograms./l. or less. Most importantly, such a threshold level of serum PSA retains only 19% of the whole cohort as candidates for transrectal ultrasonography and expensive diagnostic procedures, thus leading to the finding of 1 prostate cancer of 4 such examinations. The present data indicate that simple measurement of serum PSA can be used efficiently as a pre-screening test for prostate cancer in the general population to identify, at a low cost, the subpopulation of men at a much greater risk of having prostate cancer, and who should then be submitted to the more elaborate and expensive diagnostic procedures.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The meaning and use of the area under a receiver operating characteristic (ROC) curve.
Hanley, J. A., & McNeil, B. J. (1982) · Radiology · doi:10.1148/radiology.143.1.7063747 · Cited by 21,856
Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate
Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freiha, F. S., & Redwine, E. (1987) · New England Journal of Medicine · doi:10.1056/nejm198710083171501 · Cited by 2,451
Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer
Catalona, W. J., Smith, D. S., Ratliff, T. L., Dodds, K. M., Coplen, D. E., Yuan, J. J. J., Petros, J. A., & Andriole, G. L. (1991) · New England Journal of Medicine · doi:10.1056/nejm199104253241702 · Cited by 2,361
Clinical Epidemiology: The Essentials.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-825_10 · Cited by 1,835
A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma
Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., & Goodman, P. J. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908173210702 · Cited by 1,464
Beyond Normality: The Predictive Value and Efficiency of Medical Diagnoses.
(1977) · Annals of Internal Medicine · doi:10.7326/0003-4819-86-4-513_1 · Cited by 1,370
Walsh, P. C., Lepor, H., & Eggleston, J. C. (1983) · The Prostate · doi:10.1002/pros.2990040506 · Cited by 1,047
Clinical epidemiology: The essentials
Valagussa, P. (1988) · Controlled Clinical Trials · doi:10.1016/0197-2456(88)90054-2 · Cited by 916
Important Advances in Oncology: 1986
Merrill, J. M. (1986) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1986.03380040106043 · Cited by 907
Stamey, T. A., Kabalin, J. N., Mcneal, J. E., Johnstone, I. M., Freiha, F., Redwine, E. A., & Yang, N. (1989) · Journal of Urology · doi:10.1016/s0022-5347(17)41175-x · Cited by 871
Cooner, W. H., Mosley, B. R., Rutherford, C. L., Beard, J. H., Pond, H. S., Terry, W. J., Igel, T. C., & Kidd, D. D. (1990) · Journal of Urology · doi:10.1016/s0022-5347(17)40211-4 · Cited by 767
Boring, C. C., Squires, T. S., & Tong, T. (1991) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.41.1.19 · Cited by 617
PATTERNS OF PROGRESSION IN PROSTATE CANCER
Mcneal, J., Kindrachuk, R., Freiha, F., Bostwick, D., Redwine, E., & Stamey, T. (1986) · The Lancet · doi:10.1016/s0140-6736(86)90715-4 · Cited by 582
Oesterling, J. E., Chan, D. W., Epstein, J. I., Kimball, A. W., Bruzek, D. J., Rock, R. C., Brendler, C. B., & Walsh, P. C. (1988) · The Journal of Urology · doi:10.1016/s0022-5347(17)42630-9 · Cited by 573
Complete androgen blockade for the treatment of prostate cancer.
Labrie, F., Dupont, A., & Bèlanger, A. (1985) · PubMed · Cited by 281
Self-citationProstate cancer: comparison of transrectal US and digital rectal examination for screening.
Lee, F., Littrup, P. J., Torp-Pedersen, S. T., Mettlin, C., McHugh, T. A., Gray, J. M., Kumasaka, G. H., & McLeary, R. D. (1988) · Radiology · doi:10.1148/radiology.168.2.3293108 · Cited by 270
Lee, F., McLeary, R. D., Kumasaka, G. H., Borlaza, G. S., Straub, W. H., Gray, J. M., Meadows, T. R., Lee, F., Solomon, M. H., McHugh, T. A., et al. (1985) · The Prostate · doi:10.1002/pros.2990070202 · Cited by 237
Lee, F., Torp-Pedersen, S., Littrup, P. J., McLeary, R. D., McHugh, T. A., Smid, A. P., Stella, P. J., & Borlaza, G. S. (1989) · Radiology · doi:10.1148/radiology.170.1.2462262 · Cited by 180
Chan, D. W., Bruzek, D. J., Oesterling, J. E., Rock, R. C., & Walsh, P. C. (1987) · Clinical Chemistry · doi:10.1093/clinchem/33.10.1916 · Cited by 171
Scott, R. S., Mutchnik, D. L., Laskowski, T. Z., & Schmalhorst, W. R. (1969) · The Journal of Urology · doi:10.1016/s0022-5347(17)62388-7 · Cited by 155
Labrie, F., Dupont, A., Bélanger, A., & Lachance, R. (1987) · The Journal of Urology · doi:10.1016/s0022-5347(17)43380-5 · Cited by 122
Self-citationBenefits of Combination Therapy with Flutamide in Patients Relapsing after Castration
Labrie, F., Dupont, A., Giguère, M., Borsanyi, J.-P., Lacourcière, Y., Monfette, G., Emond, J., & Bergeron, N. (1988) · British Journal of Urology · doi:10.1111/j.1464-410x.1988.tb13971.x · Cited by 69
Self-citationSerum Prostatic Antigen Measurement in Localized Prostatic Cancer: Correlation with Clinical Course
Pontes, J. E., Chu, T. M., Slack, N. H., Karr, J., & Murphy, G. P. (1982) · The Journal of Urology · doi:10.1016/s0022-5347(17)53431-x · Cited by 64
Prostatic Carcinoma: An Autopsy Study
Lundberg, S., & Berge, T. (1970) · Scandinavian Journal of Urology and Nephrology · doi:10.3109/00365597009137581 · Cited by 50
Pinault, S., Têtu, B., Gagnon, J., Monfette, G., Dupont, A., & Labrie, F. (1992) · Urology · doi:10.1016/0090-4295(92)90301-c · Cited by 36
Self-citationLHRH Agonists and Antiandrogens in Prostate Cancer
Labrie, F., Dupont, A., & Bélanger, A. (1987) · Cancer treatment and research · doi:10.1007/978-1-4613-2033-3_15 · Cited by 29
Self-citationStatistical methods in medical diagnosis.
Cb, B. (1986) · PubMed · Cited by 29
Cited by
Ilic, D., Neuberger, M. M., Djulbegovic, M., & Dahm, P. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004720.pub3 · Cited by 1,150
Biology of Prostate-Specific Antigen
Balk, S. P., Ko, Y.-J., & Bubley, G. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.083 · Cited by 718
Serial Prostatic Biopsies in Men with Persistently Elevated Serum Prostate Specific Antigen Values
Keetch, D. W., Catalona, W. J., & Smith, D. S. (1994) · Journal of Urology · doi:10.1016/s0022-5347(17)35304-1 · Cited by 546
The Clinical Usefulness of Prostate Specific Antigen: Update 1994
Partin, A. W., & Oesterling, J. E. (1994) · Journal of Urology · doi:10.1016/s0022-5347(17)32422-9 · Cited by 390
Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force
Harris, R., & Lohr, K. N. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-11-200212030-00014 · Cited by 348
Metadata
- Authors
- Labrie, F., Dupont, A., Suburu, R., Cusan, L., Tremblay, M., Gomez, J.-L., & Emond, J.
- Venue
- Journal of Urology
- Published
- 1992-03
- Volume
- 147
- Issue
- 3 Part 2
- Pages
- 846-851
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W1455378812
- Cited by
- 337
- References
- 27
- FWCI
- 37.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.